A, Tumor growth in CXCR2myeΔ/Δ
mice. CXCR2myeΔ/Δ mice peritoneally treated with CD8a
mAb (CD8) (n=6) or control IgG (n=6) daily for the first three days then
maintained twice weekly. Three days after antibody treatment, mice were injected
intravenously with 1×106 PyMT cells. Three weeks after, the
mice were sacrificed, and the weight of the tumor-bearing lung was assessed.
B, Representative photo of lungs from tumor-bearing mice
treated with CD8 mAb or IgG control. Tumor-free lungs also shown.
C, CD8+ T-cell cytotoxicity ex vivo.
CD8+ T cells isolated from tumor-bearing lungs of
CXCR2myeΔ/Δ and CXCR2WT mice (n=3) as
effector cells (E) cocultured with firefly luciferase (luc)-expressing target
tumor cells (T) at the indicated E:T ratios. After 18 hours, luciferase activity
in the remaining PyMT-luc cells was determined to estimate viable tumor cells
and %CD8+ T-cell killing was calculated. D, MDSCs
isolated from tumor-bearing lungs of CXCR2myeΔ/Δ or
CXCR2WT mice (n=3) were cocultured with CD8+ T cells
from lung tumor of CXCR2myeΔ/Δ or CXCR2WT
mice at ratio 1:1 for 3 days and then CD8+ T cells were analyzed by
flow cytometry. E, Representative histograms of CD8+
T-cell surface markers (cells from D). F, MDSCs from tumor-bearing
lungs of CXCR2myeΔ/Δ or CXCR2WT mice and
CD8+ T cells from lung tumor of
CXCR2myeΔ/Δ mice (n=3) at the indicated ratios were
cocultured with PyMT-luc cells. After 3 days, luciferase activity was measured,
and %CD8+ T-cell killing was calculated. G, MDSCs from
tumor-bearing lungs of CXCR2myeΔ/Δ or
CXCR2WT mice were cocultured with PyMT-luc cells at the indicated
ratios. After 18 hours, luciferase activity in PyMT-luc cells was determined.
Data were analyzed using the two-sample t-test with unequal variances for panels
(A) and (D)(p values indicated); two-way ANOVA with a post-hoc test for panels
(C), (F), and (G); *p<0.05,
**p<0.01, ***p<0.001.
Experiments were repeated, and values represent mean±SD.